NAMUR, Belgium, Oct. 11, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer, today announced that research presented at the European Society for Medical Oncology Congress (ESMO) shows that Volition's novel blood test for colorectal cancer combined with the conventional faecal immunochemical screening test has the potential to offer up to a 25% reduction in colonoscopies while maintaining almost 97% detection of colorectal cancer when combined with the faecal immunochemical test (FIT) score.
Dr. Marielle Herzog, Volition's lead scientist for Nucleosomics®, presented a poster on the results from the first 2000 of the 8000 FIT positive patients in this study. This prospective screening study, conducted in conjunction with Hvidovre Hospital, University of Copenhagen, aims to discover the ability of the Nu.QTM Colorectal Cancer Screening Triage Test (blood test) to identify patients with a false positive on their FIT, in order to reduce the total number of colonoscopy referrals.
Less than 10% of people with a positive FIT score have colorectal cancer; a positive FIT score is not a diagnostic for cancer but means simply that blood has been found in the stool. This means that there are a significant number of unnecessary, expensive and invasive colonoscopies performed, placing a burden on both the patient and healthcare system. The combination of FIT test and the Nu.QTM Triage Test in the study identified nearly 97% of colorectal cancers in FIT positive subjects. By utilizing this regimen, screening programs could reduce the number of unnecessary colonoscopies performed and more importantly, for the same number of colonoscopies potentially increase screening subject throughput by up to 33%, which could result in a net increase in total CRC cases detected by up to 29%. Please note that the Poster and Presentation from ESMO are available in the Technology section of the Volition website.
Currently in Denmark, around 20,000 people have a positive faecal test for colorectal cancer each year. All of them are referred for a colonoscopy, however, statistics demonstrate that only approximately 1,000 of them have cancer and require urgent diagnosis.
The lead author of the study, Dr. Marielle Herzog, commented: "False positives add to an already long waiting list and delays diagnosis for patients who have cancer and need swift treatment. By undertaking this simple, cost effective blood test in people with a positive faecal test, we can help prevent unneeded referrals for colonoscopy with a small reduction in cancer detection and potentially reduce the colonoscopy waiting time for those at high risk of cancer."
Volition plans initially to focus the launch of its Nu.QTM Colorectal Cancer Screening Triage Test in the EU member states, which have an aggregate screening age population of approximately 148 million patients. There are organized colorectal cancer screening programs in 14 of the 28 EU states with a further 10 states offering some form of public or privately accessible screening.
Louise Day, Chief Marketing and Communications Officer said, "The introduction of Nu.QTM to help physicians decide whether patients need to go on to have a colonoscopy has the potential to significantly alleviate some of the capacity pressures within healthcare systems. Our hope is that more people will be able to be screened and more colorectal cancer cases identified early. The poster presented at ESMO this week has generated a lot of interest and discussion. We expect to receive CE Marking for this test later this year and aim to market it throughout Europe in 2017."
Volition is a life sciences company focused on developing diagnostic tests for cancer. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.
Volition's goal is to make the tests as easy and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. Volition's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
Louise Day, Volition
+44 (0)7557 774620
Scott Powell, Volition
+1 (646) 650 1351
Tirth Patel, Edison Advisors
+1 (646) 653 7035
Rachel Carroll, Edison Advisors
+44 (0)20 3077 5711
Sarah Roberts, Vane Percy & Roberts
+44 (0)1737 821 890
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics®, NuQ® and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
SOURCE VolitionRx Ltd